- Research article
- Open Access
Exercise and resveratrol increase fracture resistance in the 3xTg-AD mouse model of Alzheimer’s disease
BMC Complementary and Alternative Medicine volume 19, Article number: 39 (2019)
Alzheimer’s disease (AD) and osteoporosis are progressive diseases that affect the elderly population. Both conditions are associated with fracture risk that is greater than twice that of the healthy population. Resveratrol and exercise are two treatments that have been linked with attenuation of age-related diseases, including the risk of bone fractures. In this study, we test the hypothesis that these treatments improve fracture resistance in a mouse model representative of the AD condition.
Three-month-old male 3xTg-AD mice were treated for 4 months with resveratrol or exercise or both combined, and compared with wild type mice. Exercise training was performed on a treadmill at 15 m/min for 45 min/day, 5 days/week. Resveratrol was given at 4 g/kg diet in the form of pellets. Three-point bending, cross-sectional geometric, and fluorescence analyses were conducted on tibias and compared by treatment group.
Tibias of 3xTg mice exhibited signs of diminished bone quality and fracture under less force than age-matched wild type mice (P < 0.05). Treatment with both resveratrol and exercise improved indicators of fracture resistance and bone quality in AD mice to levels comparable to that of wild type mice (P < 0.05).
The 3xTg mouse model of AD is at elevated risk for limb bone fracture compared to wild type controls. Treatment with resveratrol, exercise, or both in combination improves fracture resistance and cross-sectional geometric indicators of bone strength.
Alzheimer’s disease (AD) is the fifth leading cause of death in the United States and is on the rise worldwide [1, 2]. AD is characterized by progressive cognitive decline associated with synaptic dysfunction and the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles in brain tissue . Osteoporosis is another age-related disease that affects millions of adults around the world over the age of 65 . Osteoporosis is a degenerative disease that results in the loss of bone mineral density and is associated with increased fracture risk and mortality . AD and osteoporosis share risk factors and etiologies, and the incidence of either one increases the risk of developing the other [6,7,8]. When both diseases are present, population studies have shown an increased mortality risk in comparison to non-AD patients alone .
There is mounting evidence indicating that regular physical activity and a diet rich in polyphenols have the potential to impact a variety of age-related human diseases. Epidemiological and clinical studies indicate that exercise can prevent the onset or slow the progression of neurodegenerative and metabolic diseases, including AD and osteoporosis [10,11,12]. These studies also emphasize the importance of polyphenol-rich diets for the management of osteoporosis [13,14,15]. Resveratrol (3,5,4-trihydroxy-trans-stilbene) is a naturally occurring polyphenol found in relatively high concentrations in grapes, seeds, and nuts is known to exert significant bone-protective effects . Specifically, dietary resveratrol activates antioxidative and osteoblastic proliferative pathways (SIRT1 and Fox01), increasing biochemical indicators of bone quality and stimulating osteogenesis to improve bone mineral density in osteoporotic animals [17,18,19]. Activation of the SIRT1 pathway by resveratrol also improves cognitive and memory deficits and is being investigated as a treatment for AD . However, exercise and resveratrol treatment, either alone or in combination, have yet to be studied in regards to their potential ability to reduce AD-related fracture risk. In this study, we test the efficacy of resveratrol and/or exercise in ameliorating fracture risk in the 3xTg-AD mouse model for AD. In this study, we examine multiple indicators of bone strength and quality to determine their effects on resistance to limb bone fracture.
Three-month-old male triple-transgenic mice (3xTg-AD) harboring three mutant genes; amyloid-β precursor protein, presenilin-1, and tau, were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Non-transgenic, aged-matched, wild type littermates (B6129SS2/J) served as a control. After a one-week period of acclimation, mice were randomly assigned to the following groups: control (n = 10), 3xTg-AD control (n = 7), 3xTg-AD treated with resveratrol (n = 8), 3xTg-AD with exercise (n = 8), and 3xTg-AD treated with a combination of resveratrol and exercise (n = 8). Duration of treatment was 4 months, after which mice were sacrificed by asphyxiation using compressed CO2 at a flow rate of 1 L/min and chamber fill rate of 30% chamber volume per minute. Throughout the experiment, mice were housed in an animal facility at a temperature of 22 °C and a 12-h light/dark cycle and given food and water ad libitum. Animal use was approved by the Institutional Animal Care and Use Committee at Midwestern University and adhered to the guidelines in the National Institutes of Health’s Guide for the Care and Use of Laboratory Animals.
Mice in the resveratrol groups were administered resveratrol (Lalilab Inc., Durham, NC, USA) in diet (4 g/kg, AIN-93G, Dyets Inc., Bethlehem, PA), while the control group received regular diet without resveratrol. The resveratrol dosage was selected based on previous studies showing this amount provides sufficient bioavailability to have an active effect with dietary administration in mice (equivalent to ∼146 mg kg− 1 day− 1) [21, 22]. In addition, this dosage exerts an insulin-mimetic effect, reduces oxidative stress, and activates the SIRT1 anti-apoptotic signaling pathway [22,23,24].
Exercise training consisted of forced running on a motor-driven treadmill designed for mice (Exer 3/6 treadmill; Columbus Instruments, Columbus, OH, USA). Mice were initially placed in separate lanes of the treadmill while it was off (0 m/min) and gradually acclimated to daily 10-min running sessions at 10 m/min for a period of one week. The duration and intensity were increased to 20 min at 10 m/min on week 2, followed by 30 min at 12 m/min on week 3. From week 4 to the end of the training regimen, running activity consisted of 45 min at 15 m/min, 5 day/week, corresponding to an estimated submaximal VO2 of ~ 50 mL/kg/min . At this intensity, mice were running without reluctance and were able to continue for the entire 45-min session.
Three-point bending test
Following sacrifice, tibias were harvested and cleaned of soft tissue. Tibial length and midshaft diameter were measured using digital calipers. Right tibias were subjected to three-point bending until failure to evaluate resistance to fracture as previously described . A load was applied to the midshaft of the tibias using a round-edged tip in the anterior-posterior axis at a rate of .05 N/s (HP-5 Force Gauge and HSV Test Stand; Handpi Instruments Co., Ltd., China). Tibias were mounted on supports that were positioned to contact the proximal and distal ends. The span between the supports was varied such that they were located at the same relative distance along the length of the tibia. This enables standardization of the location of the loading point, because load-to-fracture is proportional to the distance between the supports and the diameter of the bone in the breaking plane. At the conclusion of the bending test, data on ultimate force, ultimate stress, maximum bending moment, stiffness, and elastic modulus were recorded. Ultimate force and ultimate stress are the maximum force and stress values recorded values during the test, and usually occurred around the time of fracture. Maximum bending moment is the largest rotational force that causes bending. Stiffness and elastic modulus are measures of the stress-strain relationship for a given material that reflects how it deforms under loading.
After sacrifice, left tibias were measured and a pencil mark was made at midshaft such that the midshaft could be identified during sectioning. Tibias were then dehydrated in graded alcohol and cleared (Histoclear, National Diagnostics, Atlanta, Georgia, USA) in two 24-h washes. Bone tissue was infiltrated with catalyzed Osteo-Bed Resin A for 2 days and then submerged in Osteo-bed resin (Polysciences Inc., Warrington, PA, USA). Polymerization of the resin was in a bead bath held at 33.5 °C for 4 days. Following hardening, an undecalcified transverse section of the tibial midshaft was made at a thickness of 100 μm using a low speed saw (Isomet; Buehler, Lake Bluff, IL, USA) and polished with a fine cloth pad (MetaServ; Buehler, Lake Bluff, IL, USA). Sections were imaged under bright field microscopy at 4X magnification. The MomentMacroJ plugin (M Warfel and S Serafin) for ImageJ v1.8 (NIH) was used to measure total area (Tt.Ar) cortical area (Ct.Ar), and medullary area (M.Ar) of the tibial midshaft, and to calculate maximum and minimum second moments of area (Imax and Imin) and polar moment of area (J). Ct.Ar, Imax and Imin, and J are cross-sectional properties that measure a long bone’s ability to resist compressive, bending, and torsional loads, respectively.
Undecalcified tibial sections were imaged with fluorescence microscopy to quantify fluorescence. Corrected total bone fluorescence (CTBF) was calculated in ImageJ v1.8 as the product of the cross-sectional area of the tibia and the mean gray value of the bone standardized to the mean background color. This formula is adapted from the method used to obtain total corrected cell fluorescence in intracellular immunofluorescence studies [27, 28]. Fluorescence in bone is a reflective of post-translational modification of structural proteins, primarily collagen type I, through nonenzymatic glycation . The presence of such advanced glycation end-products (AGEs), which have been implicated in osteoporotic bone fractures, are positively correlated with increased fluorescence and are associated with increased fracture risk [30, 31].
Statistical analyses of the data were conducted using SPSS Statistics 25 software (IBM, USA). Comparisons between wild type and 3xTg-AD mice were made using unpaired two-sample t tests. AD treatment groups were tested against AD controls to determine if treatment significantly affected each variable. Statistical significance was set at P < 0.05. Tests of power, normality, and homogeneity of variance were conducted to ensure there was sufficient statistical power, and to reduce the likelihood of type II errors and violations of statistical assumptions of normality.
No signs of distress or poor health were observed and all mice completed the exercise regimen during the study. Therefore, no modifications were made to the study design or research protocols during the experiment and all animals were included in all of the following analyses.
Treatment with resveratrol and exercise improves fracture resistance
During three-point bending testing, tibias of AD control mice fractured under the least amount of force (Fig. 1). Ultimate force and ultimate stress were significantly lower for the tibias of AD controls than wild type mice (P < 0.05). Maximum bending moment and stiffness of AD control tibias were also significantly lower than that of wild type mice (P < 0.05). Treatment with resveratrol or exercise or both in combination increased the ultimate force, ultimate stress, and maximum bending moment in comparison to AD controls (P < 0.05). Elastic modulus did not differ between treatment groups.
Treatment with resveratrol and exercise in combination increases resistance to loading
Analysis of cross-sectional geometric properties of the tibia midshaft of 3xTg-AD mice treated with both resveratrol and exercise exhibited the greatest resistance to compression, bending and torsion loading, even greater than that of wild type mice (Table 1, P < 0.05). 3xTg-AD mice treated with resveratrol and exercise in combination also exhibited greater tibial diameter and cross-sectional total area and cortical area than 3xTg-AD controls (P < 0.05). In comparison to wild type mice, 3xTg-AD mice had smaller medullary areas (P < 0.05), but were otherwise similar in their cross-sectional profile. Treatment with resveratrol alone or exercise alone did not result in improvements in load resistance.
3xTg-AD mice have greater AGE content than wild type mice
Comparisons of CTBF show that tibias of 3xTg-AD mice have significantly greater AGE content than wild type mice (P < 0.05, Fig. 2). Treatment with resveratrol and exercise, either alone or in combination, did not result in significant differences with wild type or AD control mice (P > 0.05 in all cases). Wild type mice had the lowest CTBF while AD controls had the greatest CTBF on average.
The 3xTg-AD strain of mouse is triple transgenic, having transgenes for amyloid-β precursor protein, presenilin-1, and tauP301L. These mice exhibit signs of progressive cognitive and neuropathological deficits, and accumulation of amyloid-β and neurofibrillary tangles composed of hyperphosphorylated tau by six months of age [32, 33]. This model closely resembles the development and etiology of AD in humans. Patients with this debilitating disease also have an elevated fracture risk that is more than double the healthy population of the same age [9, 34]. To date, it is unknown if bone morphology and strength are compromised in 3xTg-AD mice. Here, we show 3xTg-AD mice tibia bones fracture under lower loads than age-matched, nontransgenic wild type counterparts. 3xTg-AD mice also display signs of reduced bone quality in comparison to wild type mice. Increased CTBF in 3xTg-AD mice indicates there is accelerated AGE accumulation in bone extracellular matrix, which has been directly linked to increased bone fragility and fracture risk [35,36,37,38]. Our findings suggest the decrease in bone quality may explain the increased fracture risk observed in 3xTg-AD mice more so than changes in bone morphology, as we find no difference in cross-sectional geometry between AD control and wild type mice. However, the cause of the increase in nonenzymatic glycation of bone proteins in 3xTg-AD mice is unknown. Evidence indicates that AGE accumulation contributes to amyloidosis in AD patients and such accumulations may be related to AGE increases in bone, but this hypothesis requires further testing .
Several investigations have focused on impeding the progression of AD-related cognitive deficits with exercise and resveratrol [13, 15, 40, 41]. These treatments are also known to have bone protective properties [42,43,44]. We applied both resveratrol and exercise training to the 3xTg-AD mice for a period of four months. Our results indicate that treatment with exercise and resveratrol, either alone and in combination, increase the maximum amount of force required to fracture tibias in comparison to AD controls. 3xTg-AD mice treated with these modalities have three-point bending test results within the range of those of wild type mice. 3xTg-AD mice treated with resveratrol and exercise also had increased bone diameter and total and cortical cross-sectional areas in comparison with untreated 3xTg-AD mice. Resveratrol has been shown to increase alkaline phosphatase activity, calcium deposition, and expression of anti-apoptotic and osteogenic regulatory proteins and transcription factors (osteocalcin, Osterix, Runx2/Cbfa1, Wnt, Sirt1) [45,46,47]. These stimulatory effects likely explicate the observed increases in bone diameter, area, and fluorescence, which contribute to the improved fracture resistance in these mice.
While we did not directly assess biochemical markers of bone quality, we measured CTBF, which reflects post-translational modification of structural collagen type I through nonenzymatic glycation. 3xTg-AD mice treated with resveratrol and exercise have CTBF values similar to wild type mice, suggesting treatment yields improvements in the quality of bone matrix. This finding is likely an effect of resveratrol treatment, which has been shown to inhibit the formation of AGEs, as well as stimulate expression of collage type I by osteoblasts [17, 48,49,50]. Of the two treatments in our study, resveratrol yields the greatest improvements in elastic modulus and stiffness, both of which are greatly affected by AGEs and are significant contributors to bone toughness . Exercise treatment has also been shown to reduce AGE formation, although the mechanism is not as well understood . Our results suggest actions of resveratrol and exercise may improve bone quality in 3xTg-AD mice, thereby improving fracture resistance.
The greatest improvement in three-point bending test results and cross-sectional geometric indicators of bone strength are observed in 3xTg-AD mice treated with exercise and resveratrol treatment. In combination, these therapies improve fracture resistance and bone strength to levels that are greater than those of untreated wild type mice. Prior studies have linked resveratrol treatment to improved aerobic performance and prevention of oxidative stress [53, 54] and increases in the activity of antioxidant enzyme systems . It may be that resveratrol augments the beneficial effects of exercise to levels above those observed with each treatment in isolation. These results indicate exercise and resveratrol together may have bone-protective benefits beyond just the AD condition, but to the broader population.
The evidence presented above suggests resveratrol and exercise may have therapeutic benefits for AD-related fracture risk. Exercise and resveratrol treatment may play a role in inhibiting the accumulation of AGEs in bone extracellular matrix to enhance bone strength and resistance to fracture.
Advanced glycation end products
Corrected total bone fluorescence
Maximum second moment of area
Minimum second moment of area
Polar moment of area
Alzheimer's Association. 2018 Alzheimer's disease facts and figures. Alzheimers Dement. 2018;14:367–29.
Wimo A, Guerchet M, Ali GC, Wu YT, Prina AM, Winblad B, Jönsson L, Liu Z, Prince M. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017;13:1–7.
Kumar A. Singh a. A review on Alzheimer's disease pathophysiology and its management: an update. Pharmacol Rep. 2015;67:195–203.
Briggs AM, Cross MJ, Hoy DG, Sànchez-Riera L, Blyth FM, Woolf AD, March L. Musculoskeletal health conditions represent a global threat to healthy aging: a report for the 2015 World Health Organization world report on ageing and health. The Gerontologist. 2016;56:S243–55.
Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009;301:513–21.
Chen YH, Lo RY. Alzheimer's disease and osteoporosis. Tzu-Chi Med J. 2017;29:138.
Zhou R, Deng J, Zhang M, Zhou HD, Wang YJ. Association between bone mineral density and the risk of Alzheimer's disease. J Alzheimers Dis. 2011;24:101–8.
Zhou R, Zhou H, Rui L, Xu J. Bone loss and osteoporosis are associated with conversion from mild cognitive impairment to Alzheimer’s disease. Curr Alzheimers Res. 2014;11:706–13.
Baker NL, Cook MN, Arrighi HM, Bullock R. Hip fracture risk and subsequent mortality among Alzheimer's disease patients in the United Kingdom, 1988–2007. Age Ageing. 2010;40:49–54.
Morris JK, Vidoni ED, Johnson DK, Van Sciver A, Mahnken JD, Honea RA, Wilkins HM, Brooks WM, Billinger SA, Swerdlow RH, Burns JM. Aerobic exercise for Alzheimer's disease: a randomized controlled pilot trial. PLoS One. 2017;12:e0170547.
Sawda C, Moussa C, Turner RS. Resveratrol for Alzheimer's disease. Ann N Y Acad Sci. 2017;1403:142–9.
Shen Y, Li R. What do we know from clinical trials on exercise and Alzheimer's disease? J Sport Health Science. 2016;5:397–9.
Rayalam S, Della-Fera MA, Baile CA. Synergism between resveratrol and other phytochemicals: implications for obesity and osteoporosis. Mol Nutr Food Res. 2011;55:1177–85.
Ireland A, Rittweger J. Exercise for osteoporosis: how to navigate between overeagerness and defeatism. J Musculoskelet Neuronal Interact. 2017;17:155.
Tou JC. Evaluating resveratrol as a therapeutic bone agent: preclinical evidence from rat models of osteoporosis. Ann N Y Acad Sci. 2015;1348:75–85.
Serafini M, Peluso I, Raguzzini A. Flavonoids as anti-inflammatory agents. Proc Nutr Soc. 2010;69:273–8.
Feng J, Liu S, Ma S, Zhao J, Zhang W, Qi W, Cao P, Wang Z, Lei W. Protective effects of resveratrol on postmenopausal osteoporosis: regulation of SIRT1-NF-κB signaling pathway. Acta Biochim Biophys Sin. 2014;46:1024–33.
Feng YL, Jiang XT, Ma FF, Han J, Tang XL. Resveratrol prevents osteoporosis by upregulating FoxO1 transcriptional activity. Int J Mol Med. 2018;41:202–12.
Tou JC. Resveratrol supplementation affects bone acquisition and osteoporosis: pre-clinical evidence toward translational diet therapy. Biochim Biophys Acta Molecular basis of disease. 1852;2015:1186–94.
Ahmed T, Javed S, Javed S, Tariq A, Šamec D, Tejada S, Nabavi SF, Braidy N, Nabavi SM. Resveratrol and Alzheimer’s disease: mechanistic insights. Mol Neurobiol. 2017;54:2622–35.
Dolinsky VW, Jones KE, Sidhu RS, Haykowsky M, Czubryt MP, Gordon T, Dyck JR. Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. J Physiol. 2012;590:2783–99.
Dolinsky VW, Rueda-Clausen CF, Morton JS, Davidge ST, Dyck JR. Continued postnatal administration of resveratrol prevents diet-induced metabolic syndrome in rat offspring born growth restricted. Diabetes. 2011;60:2274–84.
Zhang H, Zhang J, Ungvari Z, Zhang C. Resveratrol improves endothelial function: role of TNFα and vascular oxidative stress. Arterioscler Thromb Vasc Biol. 2009;29:1164–71.
Liao ZY, Chen JL, Xiao MH, Sun Y, Zhao YX, Pu D, Lv AK, Wang ML, Zhou J, Zhu SY, Zhao KX. The effect of exercise, resveratrol or their combination on sarcopenia in aged rats via regulation of AMPK/Sirt1 pathway. Exp Gerontol. 2017;98:177–83.
Høydal MA, Wisløff U, Kemi OJ, Ellingsen O. Running speed and maximal oxygen uptake in rats and mice: practical implications for exercise training. Eur J Cardiovasc Prev Rehabil. 2007;14:753–60.
Odle B, Dennison N, Al-Nakkash L, Broderick TL, Plochocki JH. Genistein treatment improves fracture resistance in obese diabetic mice. BMC Endocr Disord. 2017;17:1.
Gavet O, Pines J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell. 2010;18:533–43.
McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A. Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events. Cell Cycle. 2014;13:1400–12.
Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone. 2001;28:195–201.
Vashishth D. Advanced glycation end-products and bone fractures. IBMS Bonekey. 2009;6:268–78.
Yamagishi SI. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets. 2011;12:2096–102.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003;39:409–21.
Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron. 2004;45:675–88.
Melton LJ, Beard CM, Kokmen E, Atkinson EJ, O'Fallon WM. Fracture risk in patients with Alzheimer's disease. J Amer Geriatr Soc. 1994;42:614–9.
Viguet-Carrin S, Roux JP, Arlot ME, Merabet Z, Leeming DJ, Byrjalsen I, Delmas PD, Bouxsein ML. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone. 2006;39:1073–9.
Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone. 2002;31:1–7.
Poundarik AA, Wu PC, Evis Z, Sroga GE, Ural A, Rubin M, Vashishth D. A direct role of collagen glycation in bone fracture. J Mech Behav Biomed Mater. 2015;52:120–30.
Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone. 2007;40:1144–51.
Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A. 1994;91:4766–70.
Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci. 2005;25:4217–21.
Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX, Stern Y. Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009;302:627–37.
Cooley J, Broderick TL, Al-Nakkash L, Plochocki JH. Effects of resveratrol treatment on bone and cartilage in obese diabetic mice. J Diabetes Metab Disord. 2015;14:10.
Guadalupe-Grau A, Fuentes T, Guerra B, Calbet JA. Exercise and bone mass in adults. Sports Med. 2009;39:439–68.
Ornstrup MJ, Harslof T, Kjaer TN, Langdahl BL, Pedersen SB. Resveratrol increases bone mineral density and bone alkaline phosphatase in obese men: a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2014;99:4720–9.
Abed É, Delalandre A, Lajeunesse D. Beneficial effect of resveratrol on phenotypic features and activity of osteoarthritic osteoblasts. Arthritis Res Ther. 2017;19:151.
Dai Z, Li Y, Quarles LD, Song T, Pan W, Zhou H, Xiao Z. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine. 2007;14:806–14.
Zhou H, Shang L, Li X, Zhang X, Gao G, Guo C, Chen B, Liu Q, Gong Y, Shao C. Resveratrol augments the canonical Wnt signaling pathway in promoting osteoblastic differentiation of multipotent mesenchymal cells. Exp Cell Res. 2009;315:2953–62.
Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys. 2003;419:63–79.
Wu CH, Yen GC. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. J Agric Food Chem. 2005;53:3167–73.
Yeh WJ, Hsia SM, Lee WH, Wu CH. Polyphenols with antiglycation activity and mechanisms of action: a review of recent findings. J Food Drug Anal. 2017;25:84–92.
Rubin MR, Paschalis EP, Poundarik A, Sroga GE, McMahon DJ, Gamsjaeger S, Klaushofer K, Vashishth D. Advanced glycation endproducts and bone material properties in type 1 diabetic mice. PLoS One. 2016;11:e0154700.
Boor P, Celec P, Behuliak M, Grančič P, Kebis A, Kukan M, Pronayová N, Liptaj T, Ostendorf T, Šebeková K. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metab Clin Exp. 2009;58:1669–77.
Baltaci SB, Mogulkoc R, Baltaci AK. Resveratrol and exercise. Biomed Rep. 2016;5:525–30.
Hart N, Sarga L, Csende Z, Koltai E, Koch LG, Britton SL, Davies KJ, Kouretas D, Wessner B, Radak Z. Resveratrol enhances exercise training responses in rats selectively bred for high running performance. Food Chem Toxicol. 2013;61:53–9.
Rege SD, Kumar S, Wilson DN, Tamura L, Geetha T, Mathews ST, Huggins KW, Broderick TL, Babu JR. Resveratrol protects the brain of obese mice from oxidative damage. Oxidative Med Cell Longev. 2013;2013.
The authors greatly appreciate the assistance of Kelly Ezell. We also wish to acknowledge Midwestern University Intramural Funds (LA, TLB, and JP) for contributing to funding our research.
Diabetes Action Research and Education Foundation (TBL) and Midwestern University (TBL, LA, JHP) provided funding for the animals used in the study. The funding agencies had no role in the study design or the collection, analysis, and interpretation of the data.
Availability of data and materials
The datasets used in the current study are available from the corresponding author by request.
The protocol for this study was approved by the Midwestern University Institution Animal Care and Use Committee (IACUC protocol 2565).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Alkhouli, M.F., Hung, J., Squire, M. et al. Exercise and resveratrol increase fracture resistance in the 3xTg-AD mouse model of Alzheimer’s disease. BMC Complement Altern Med 19, 39 (2019). https://doi.org/10.1186/s12906-019-2451-6